LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | SU11274 | 10 | uM | LJP5 | 2 | J07 | 72 | hr | 2543 | 2430 | 5761 | 0.4218 | -0.0379 |
| SK-BR-3 | SU11274 | 10 | uM | LJP5 | 3 | J07 | 72 | hr | 2543 | 2524 | 5760 | 0.4381 | -0.0065 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 1 | H12 | 72 | hr | 2543 | 2600 | 5258 | 0.4944 | 0.0212 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 2 | H12 | 72 | hr | 2543 | 2707 | 5438 | 0.4978 | 0.0585 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 3 | H12 | 72 | hr | 2543 | 2702 | 5557 | 0.4862 | 0.0551 |
| SK-BR-3 | Canertinib | 0.12 | uM | LJP6 | 1 | H11 | 72 | hr | 2543 | 2277 | 5258 | 0.4330 | -0.1002 |
| SK-BR-3 | Canertinib | 0.12 | uM | LJP6 | 2 | H11 | 72 | hr | 2543 | 2322 | 5438 | 0.4270 | -0.0797 |
| SK-BR-3 | Canertinib | 0.12 | uM | LJP6 | 3 | H11 | 72 | hr | 2543 | 2188 | 5557 | 0.3937 | -0.1250 |
| SK-BR-3 | Canertinib | 0.37 | uM | LJP6 | 1 | H10 | 72 | hr | 2543 | 2041 | 5258 | 0.3881 | -0.1894 |
| SK-BR-3 | Canertinib | 0.37 | uM | LJP6 | 2 | H10 | 72 | hr | 2543 | 1946 | 5438 | 0.3578 | -0.2167 |
| SK-BR-3 | Canertinib | 0.37 | uM | LJP6 | 3 | H10 | 72 | hr | 2543 | 1963 | 5557 | 0.3532 | -0.2053 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 1 | H09 | 72 | hr | 2543 | 1766 | 5258 | 0.3358 | -0.2940 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 2 | H09 | 72 | hr | 2543 | 1855 | 5438 | 0.3411 | -0.2502 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 3 | H09 | 72 | hr | 2543 | 1904 | 5557 | 0.3426 | -0.2265 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 1 | H08 | 72 | hr | 2543 | 1834 | 5258 | 0.3487 | -0.2681 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 2 | H08 | 72 | hr | 2543 | 1807 | 5438 | 0.3323 | -0.2679 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 3 | H08 | 72 | hr | 2543 | 1724 | 5557 | 0.3102 | -0.2917 |
| SK-BR-3 | Canertinib | 10 | uM | LJP6 | 1 | H07 | 72 | hr | 2543 | 1515 | 5258 | 0.2881 | -0.3901 |
| SK-BR-3 | Canertinib | 10 | uM | LJP6 | 2 | H07 | 72 | hr | 2543 | 1477 | 5438 | 0.2716 | -0.3909 |
| SK-BR-3 | Canertinib | 10 | uM | LJP6 | 3 | H07 | 72 | hr | 2543 | 1533 | 5557 | 0.2759 | -0.3617 |
| SK-BR-3 | NVP-AEW541 | 0.04 | uM | LJP5 | 1 | E18 | 72 | hr | 2543 | 5902 | 5734 | 1.0292 | 1.0497 |
| SK-BR-3 | NVP-AEW541 | 0.04 | uM | LJP5 | 2 | E18 | 72 | hr | 2543 | 5963 | 5761 | 1.0350 | 1.0592 |
| SK-BR-3 | NVP-AEW541 | 0.04 | uM | LJP5 | 3 | E18 | 72 | hr | 2543 | 5900 | 5760 | 1.0242 | 1.0409 |
| SK-BR-3 | NVP-AEW541 | 0.12 | uM | LJP5 | 1 | E17 | 72 | hr | 2543 | 5653 | 5734 | 0.9858 | 0.9757 |
| SK-BR-3 | NVP-AEW541 | 0.12 | uM | LJP5 | 2 | E17 | 72 | hr | 2543 | 5787 | 5761 | 1.0044 | 1.0075 |